<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="217466">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00253786</url>
  </required_header>
  <id_info>
    <org_study_id>DNETT-Japan</org_study_id>
    <nct_id>NCT00253786</nct_id>
  </id_info>
  <brief_title>Study for the Effectiveness of Intensive Therapy Aiming at a Remission of Diabetic Nephropathy</brief_title>
  <official_title>Study for the Effectiveness of Intensive Therapy for Diabetic Nephropathy in Unblinded, Randomized Intergroup Comparison Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Okayama University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Okayama University</source>
  <brief_summary>
    <textblock>
      Study for the effectiveness of intensive therapy aiming at the remission of diabetic
      nephropathy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study for the effectiveness of intensive therapy for diabetic nephropathy in unblinded,
      randomized intergroup comparison study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2005</start_date>
  <completion_date>June 2011</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Protein/creatinine ratio in albuminuria(first urine in early-morning)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protocol A:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GFR</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular event</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of retinopathy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin/creatinine ratio</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albuminuria (collected for 24 hrs.)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protocol B:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein/creatinine ratio</measure>
  </secondary_outcome>
  <enrollment>600</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Diabetic Nephropathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE inhibitors,ARB, HMG-CoA reductase inhibitors, vitamins</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Compliance, antismoking, and nutrition instruction</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Urinary albumin/creatinine ratio &gt;= 300mg/gCr

          -  Serum creatinine level &lt;2.5mg/dL through the observation period

          -  Patients whose consent is obtained at age &gt;20 years or =&lt;75 years

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Hereditary diabetes mellitus or secondary diabetes mellitus

          -  Non-diabetic nephropathy

          -  Familial hypercholesterolemia

          -  Secondary hypertension

          -  Unstable angina pectoris

          -  Myocardial infarction

          -  Cerebral hemorrhage

          -  Life-threatening disease such as malignant tumor

          -  History of angioedema

          -  Under LDL-apheresis by a adsorbent with dextran sulphate cellose

          -  Biliary obstruction

          -  Severe hepatopathy

          -  Hypergasia of hepatic metabolism such as acute hepatitis

          -  Exacerbation of chronic hepatitis

          -  Cirrhosis

          -  Hepatic cancer

          -  Jaundice

          -  History of hypersensitivity against ACE inhibitors

          -  History of hypersensitivity against ARB

          -  History of hypersensitivity against HMG-CoA reductase inhibitors

          -  Pregnant, lactating, and probably pregnant patients

          -  Patients who want to become pregnant during the study period

          -  Patients judged as being inappropriate for the subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hirofumi Makino, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kenichi Shikata, M.D.</last_name>
    <phone>086-235-7235</phone>
    <email>shikata@md.okayama-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenichi Shikata, M.D.</last_name>
      <phone>086-235-7235</phone>
      <email>shikata@md.okayama-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Hirofumi Makino, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <lastchanged_date>January 15, 2007</lastchanged_date>
  <firstreceived_date>November 10, 2005</firstreceived_date>
  <keyword>diabetes</keyword>
  <keyword>nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
